Clinical trials: Nasal Polyposis
Bilateral Nasal Polyposis
Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Using a Novel Bi-directional Device
The primary objective of this study was to compare the efficacy of intranasal administration of 100, 200, and 400 μg twice daily (bid) of fluticasone propionate, delivered by the Optinose device, with matching placebo in subjects…
- Trial name
- NCT01624662
- Testing
- Fluticasone propionate
- Where
- 10 sites in United States
- Volunteers
- 323 people
- Sponsor
- Optinose US Inc.
Rhinosinusitis
Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis
The study should create data for the selection of a clinically relevant endpoint to assess the potential of Buparid/PARI SINUS to postpone sinus surgery in patients with chronic Rhinosinusitis.
- Trial name
- NCT01955980
- Testing
- Budesonide
- Where
- 3 sites in Germany
- Volunteers
- 19 people
- Sponsor
- Pari Pharma GmbH
Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps
Primary Objective: To evaluate the efficacy of dupilumab 300 mg every 2 weeks (q2w) compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion (NC)/obstruction severity and…
- Trial name
- SINUS-52 (NCT02898454)
- Testing
- Dupilumab SAR231893 (REGN668), Mometasone furoate nasal spray
- Where
- 123 sites in United States, Argentina and 12 more
- Volunteers
- 448 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyps
Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)
This was a Phase 4, open-label, single-arm, multicenter study to evaluate the efficacy and safety of dupilumab subcutaneous (SC) injection monotherapy in Japanese participants aged 18 or older with CRSwNP that is not adequately…
- Trial name
- NCT05049122
- Testing
- Dupilumab SAR231893
- Where
- Japan
- Volunteers
- 25 people
- Sponsor
- Sanofi
Bilateral Nasal Polyposis
A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis
The study will evaluate the effect of ACT-774312 on the nasal polyps and will assess the safety and tolerability of ACT-774312 in the patients with bilateral nasal polyposis
- Trial name
- NCT03688555
- Testing
- ACT-774312
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 10 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Nasal Polyposis
Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis
The aim of this present study is to investigate the use of benralizumab as treatment for severe nasal polyposis. The effect of benralizumab on nasal polyps will be assessed over a 56 weeks of treatment period in patients with…
- Trial name
- OSTRO (NCT03401229)
- Testing
- Benralizumab 30 mg SC + Mometasone Furoate
- Where
- 99 sites in United States, Austria and 6 more
- Volunteers
- 413 people
- Sponsor
- AstraZeneca
Chronic Rhinosinusitis With Nasal Polyps, Asthma
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives To evaluate the efficacy of dupilumab in improving chronic…
- Trial name
- EVEREST (NCT04998604)
- Testing
- Dupilumab, Omalizumab
- Where
- 87 sites in United States, Belgium and 15 more
- Volunteers
- 360 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps
This is a 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of intranasal administration of 186 and 372 μg twice daily (BID) of OPN-375 in subjects with…
- Trial name
- NCT03781804
- Testing
- OPN-375
- Where
- 92 sites in United States, Bulgaria and 6 more
- Volunteers
- 332 people
- Sponsor
- Optinose US Inc.
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
GB001 in Adult Participants With Chronic Rhinosinusitis
A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of GB001 compared with placebo over 16 weeks of treatment in patients…
- Trial name
- NCT03956862
- Testing
- GB001
- Where
- 38 sites in United States, Czechia and 1 more
- Volunteers
- 97 people
- Sponsor
- GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
Nasal Polyps
Effect of Mepolizumab in Severe Bilateral Nasal Polyps
Nasal polyps (NP) has long been known as chronic inflammatory disease of the nasal mucosa. This disease is characterized by the presence of polyps in the upper nasal cavity, originating from within the ostiomeatal complex.
- Trial name
- NCT03085797
- Testing
- Mepolizumab, Mometasone furoate
- Volunteers
- 414 people
- Sponsor
- GlaxoSmithKline
Nasal Polyps
Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292)
The purpose of this study is to evaluate the safety and efficacy of Nasonex® (Mometasone Furoate Nasal Spray(MFNS)) in the treatment of nasal polyps in pediatric subjects between the ages of 6 and less than 18 years old.
- Trial name
- NCT00378378
- Testing
- Mometasone Furoate Nasal Spray (MFNS)
- Volunteers
- 127 people
- Sponsor
- Organon and Co
Nasal Polyps
An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis
Primary Objective: To evaluate the efficacy of dupilumab (SAR231893/REGN668) in the treatment of bilateral Nasal Polyposis (NP) by assessment of the endoscopic nasal polyp score (NPS) in comparison to placebo.
- Trial name
- NCT01920893
- Testing
- Dupilumab, Mometasone furoate nasal spray
- Where
- 14 sites in United States, Belgium and 2 more
- Volunteers
- 60 people
- Sponsor
- Sanofi
Nasal Polyps, Chronic Rhinosinusitis
A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps
The purpose of this study is to determine the efficacy and safety of omalizumab compared with placebo in adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who have had an inadequate response to…
- Trial name
- POLYP 2 (NCT03280537)
- Testing
- Omalizumab
- Where
- 45 sites in United States, Belgium and 8 more
- Volunteers
- 127 people
- Sponsor
- Hoffmann-La Roche
Chronic Rhinosinusitis With Nasal Polyps
Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis
- Trial name
- WAYPOINT (NCT04851964)
- Testing
- Experimental: Tezepelumab, Mometasone furoate or equivalent intranasal corticosteroid
- Where
- 112 sites in United States, Canada and 8 more
- Volunteers
- 416 people
- Sponsor
- AstraZeneca
Rhinosinusitis, Chronic Polyposis
Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi
The study should create data for the selection of a clinically relevant primary endpoint to assess the efficacy and safety of Buparid/PARI SINUS as compared to Budes Nasal Spray in the therapy of chronic rhinosinusitis (CRS) with…
- Trial name
- NCT01946711
- Testing
- Budesonide
- Where
- 4 sites in Germany
- Volunteers
- 14 people
- Sponsor
- Pari Pharma GmbH
Bilateral Nasal Polyposis
Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety
The primary objective of this study is to compare the efficacy of intranasal administration of 100, 200, and 400 μg of fluticasone propionate twice a day delivered by the OptiNose device with placebo in subjects with bilateral…
- Trial name
- NCT01622569
- Testing
- Fluticasone Propionate
- Where
- 33 sites in United States, Canada
- Volunteers
- 323 people
- Sponsor
- Optinose US Inc.
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis
The purpose of this study is to compare the efficacy and safety of rimegepant versus placebo in the acute treatment of chronic rhinosinusitis (CRS) with and without nasal polyps.
- Trial name
- NCT05248997
- Testing
- rimegepant 75 mg ODT
- Where
- 33 sites in United States
- Volunteers
- 261 people
- Sponsor
- Pfizer
Nasal Polyps
Qualitative Analysis of Subject Experience of Nasal Polyps
Nasal polyposis is a chronic inflammatory disease of the nose and sinuses. GlaxoSmithKline (GSK) is embarking on a clinical program to assess treatment of severe, recurrent nasal polyps with an anti-interleukin-5 (anti-IL5)…
- Trial name
- NCT03221192
- Testing
- VAS questionnaire, SNOT-22 questionnaire, Data capture app
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- GlaxoSmithKline
Nasal Polyps
Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- ANCHOR-1 (NCT05274750)
- Testing
- Depemokimab (GSK3511294)
- Where
- 105 sites in United States, Argentina and 9 more
- Volunteers
- 276 people
- Sponsor
- GlaxoSmithKline
Chronic Rhinosinusitis
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps
This is a 24-week randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of intranasal administration of 186 and 372 μg twice daily (BID) of OPN-375 in subjects with…
- Trial name
- NCT03960580
- Testing
- OPN-375
- Where
- 87 sites in United States, Australia and 8 more
- Volunteers
- 223 people
- Sponsor
- Optinose US Inc.